Bionano Genomics announced the results of an implementation study conducted by researchers at University Medical Center Groningen that compared optical genome mapping, OGM, to traditional cytogenetic methods for the detection of structural variants, SVs, in bone marrow aspirate, BMA, samples. OGM has been shown to regularly detect SVs missed by other methods, as a result of the higher resolution and sensitivity of OGM. Some of OGM’s novel findings, however, are difficult for other methods to validate, because of their resolution limitations. In this paper, researchers used OGM to detect variants in the BMA samples that were missed by traditional methods, and then applied targeted Cas9-directed Nanopore sequencing to validate the variants detected with OGM and define the breakpoints at the base pair level. The study results highlight OGM’s ability to provide researchers with a more comprehensive understanding of leukemia subtypes and the potential of targeted Cas9-directed Nanopore sequencing to validate new findings efficiently and at high resolution, compared to other genome analysis methods, including short read or other long read sequencing methods.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BNGO:
- Bionano Genomics enters partnership with Diagens
- Bionano Genomics announces publication showing OGM detects over 1250 variants
- Bionano Announces Publication Showing that OGM Detects Over 1250 Structural Variants, including 56 Gene Fusions, in Pediatric Leukemia that were Missed by Whole Genome Sequencing
- BioNano Genomics Launches Offering to Bolster Finances
- Bionano Announces $10 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules